0001209191-22-062615.txt : 20221223
0001209191-22-062615.hdr.sgml : 20221223
20221223161543
ACCESSION NUMBER: 0001209191-22-062615
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221110
FILED AS OF DATE: 20221223
DATE AS OF CHANGE: 20221223
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Session R.A. II
CENTRAL INDEX KEY: 0001701846
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39536
FILM NUMBER: 221485561
MAIL ADDRESS:
STREET 1: C/O AVEXIS, INC.
STREET 2: 2275 HALF DAY ROAD, SUITE 200
CITY: BANNOCKBURN
STATE: IL
ZIP: 60015
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc.
CENTRAL INDEX KEY: 0001806310
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 843199512
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
BUSINESS PHONE: (214) 612-0000
MAIL ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-11-10
0
0001806310
Taysha Gene Therapies, Inc.
TSHA
0001701846
Session R.A. II
C/O TAYSHA GENE THERAPIES, INC.
3000 PEGASUS PARK DRIVE, SUITE 1430
DALLAS
TX
75247
1
0
1
0
Employee Stock Option (right to buy)
1.95
2022-11-10
4
A
0
199500
0.00
A
2032-11-10
Common Stock
199500
199500
D
Represents Reporting Person's annual incentive compensation for 2021 performance awarded in the discretion of the compensation committee of the Issuer's board of directors on November 10, 2022.
25% of the total number of shares underlying the option shall vest and become exercisable on November 10, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
/s/ Kamran Alam, Attorney-in-Fact
2022-12-23